131 related articles for article (PubMed ID: 10348276)
1. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma--a critique.
Roos DE; Smith JG
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):493-5. PubMed ID: 10348276
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
3. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.
Zidan J; Hefer E; Iosilevski G; Drumea K; Stein ME; Kuten A; Israel O
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1330-6. PubMed ID: 15275717
[TBL] [Abstract][Full Text] [Related]
5. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
6. Fractionated doses of radioiodine for ablation of postsurgical thyroid tissue remnants.
Arad E; Flannery K; Wilson GA; O'Mara RE
Clin Nucl Med; 1990 Oct; 15(10):676-7. PubMed ID: 2225668
[TBL] [Abstract][Full Text] [Related]
7. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma.
Bal C; Padhy AK; Jana S; Pant GS; Basu AK
Cancer; 1996 Jun; 77(12):2574-80. PubMed ID: 8640708
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the efficacy of iodine-131 for thyroid ablation.
Comtois R; Thériault C; Del Vecchio P
J Nucl Med; 1993 Nov; 34(11):1927-30. PubMed ID: 8229236
[TBL] [Abstract][Full Text] [Related]
10. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
11. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
De Klerk JM; Oyen WJ
Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
13. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.
Doi SA; Woodhouse NJ
Clin Endocrinol (Oxf); 2000 Jun; 52(6):765-73. PubMed ID: 10848882
[TBL] [Abstract][Full Text] [Related]
14. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan.
Beierwaltes WH; Rabbani R; Dmuchowski C; Lloyd RV; Eyre P; Mallette S
J Nucl Med; 1984 Dec; 25(12):1287-93. PubMed ID: 6502251
[TBL] [Abstract][Full Text] [Related]
15. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of high-dosage radioiodine therapy in the elimination of remnant tissue following total thyroidectomy].
Schümichen C; Bulczak-Schmidt M; Blattmann H; Pauli-Harnasch C
Nuklearmedizin; 1984 Oct; 23(5):265-9. PubMed ID: 6522276
[TBL] [Abstract][Full Text] [Related]
17. [Radioiodine therapy in differentiated thyroid gland carcinoma].
Schicha H; Dietlein M
Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma.
Robbins RJ; Schlumberger MJ
J Nucl Med; 2005 Jan; 46 Suppl 1():28S-37S. PubMed ID: 15653649
[TBL] [Abstract][Full Text] [Related]
19. Acute toxicity of adjuvant radiotherapy in locally advanced differentiated thyroid carcinoma. First results of the multicenter study differentiated thyroid carcinoma (MSDS).
Schuck A; Biermann M; Pixberg MK; Müller SB; Heinecke A; Schober O; Willich N
Strahlenther Onkol; 2003 Dec; 179(12):832-9. PubMed ID: 14652672
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
Barbaro D; Boni G
Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
